Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

cquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended March 31, 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to ... single photon emission computed tomography (SPECT) according to researchers from Amen Clinics, ... over 20,000 brain scans and is believed to be the largest brain imaging study ...
(Date:7/1/2015)... ... ... next-generation sequencing (NGS) clinical market is poised for huge growth as it prepares to ... its new report that the market drivers of this vibrant industry include increased payor ... as part of a molecular diagnostics trend. , The global market is forecast to ...
(Date:7/1/2015)... 1, 2015  Axovant Sciences Ltd. (NYSE:  AXON), ... treatment of dementia, today announced that the company ... at 5:45 p.m. EDT following its presentation of ... Conference 2015 (AAIC). The event ... Dr. Lawrence Friedhoff , Chief Development Officer, ...
(Date:7/1/2015)... PHILADELPHIA , July 1, 2015 ... technology will ... s evidence-based clinical s olutions suite ... scientific, technical and medical information products and services, announced today ... -based clinical decision support (CDS) technology company. InferMed,s ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... Ariz. -- Panelists at the Demo 2003 conference offered insights ... question, "If we look back in the year 2025 what ... of the Open Source Applications Foundation, and founder of Lotus, ... in the Bio and Nano Technology space, its where the ...
... time of the chronic threat of terrorism and the possibility ... biological weapons, high on the wish list of security agencies ... detect the presence of dangerous biological agents. , ,Now, with ... at the University of Wisconsin-Madison, the age of the inexpensive, ...
... provider, today announced that it has signed an ... and services. Based on the agreement, Digital River ... support the online sales and marketing of Metrowerks' ... addition to hosting the site, Digital River is ...
Cached Biology Technology:Industry Veterans take a look back from 2025: Bio-Technology, and Bio-Informatics are the focus 2Diamond Film May Enable Critical New Sensors For Bioterror 2Diamond Film May Enable Critical New Sensors For Bioterror 3Diamond Film May Enable Critical New Sensors For Bioterror 4Digital River Provides E-Commerce Operations for Metrowerks 2
(Date:6/9/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, will be providing demonstrations of its ... Drug Information Association (DIA) Annual Meeting in ... will include previews of many exciting new enhancements that ... iMedNet 2015 Feature 1 Release. ...
(Date:6/8/2015)... June 8, 2015  Trovagene, Inc. (NASDAQ: TROV ), ... data featuring its Precision Cancer Monitoring SM platform will ... Biopsies conference in San Diego, CA ... Medicine Series: Integrating Clinical Genomics and Cancer Therapy in ... 13-16. "We continue to advance our clinical ...
(Date:6/5/2015)... Md. , June 5, 2015  Intrexon Corporation ... biology, today announced that it has determined the final ... all of its 17,830,305 shares of ZIOPHARM Oncology, Inc. ... about June 12, 2015, the distribution date, as a ... and on warrants to purchase shares of Intrexon common ...
Breaking Biology News(10 mins):MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 2Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 3Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares 4
... in obese laboratory rats may provide a less-invasive alternative ... Endocrinology . Scientists at Cincinnati Children,s Hospital ... of bile from the bile duct into the small ... bariatric surgeries such as gastric by-pass. They named the ...
... effect of different dosages of vitamin D supplementation in ... within a range recommended by some pediatric societies. However, ... lower range recommended by the Institute of Medicine, according ... JAMA , a theme issue on child health. ...
... From methanol to formaldehyde - this reaction is the ... Using catalysts made of gold particles, formaldehyde could be ... methods. Just how the mysterious gold catalyst works has ... the Ruhr-Universitt Bochum in a cooperation project. In the ...
Cached Biology News:Study finds possible alternative to bariatric weight loss surgery 2Optimal vitamin D dosage for infants uncertain 2Optimal vitamin D dosage for infants uncertain 3Mysterious catalyst explained 2
synphilin-1 (V-19)...
... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... cell culture supernates and serum.1 Each kit ... approximately fifteen 96-well plates, provided that the ...
... are designed for use with the ProQuest ... MaV203 contains deletions in the endogenous GAL4 ... two-hybrid systems. The strain also has leu2 ... bait and prey vectors. MaV203 contains three ...
Anti-Cullin-1 Host: rabbit polyclonal Species Reactivity: human, mouse Applications: IHC(P), WB, IP Storage: 4C...
Biology Products: